DX Group enters sale-and-leaseback deal with ChanceryGate Livingston

Josh White WebFG News | 22 Sep, 2017 15:08 - Updated: 15:08 | | |

cash money sterling pound

DX (Group)


12:15 13/12/17
  • 3,260.74
  • -0.16%-5.25
  • Max: 3,273.61
  • Min: 3,253.16
  • Volume: 0
  • MM 200 : n/a
13:00 13/12/17
  • 1,016.97
  • -0.29%-2.94
  • Max: 1,019.48
  • Min: 1,015.22
  • Volume: 0
  • MM 200 : n/a
13:05 13/12/17

DX Group announced on Friday that it has exchanged contracts with ChanceryGate Livingston to sell-and-leaseback certain freehold properties for an aggregate cash consideration of £4.5m.

The AIM-traded firm said that at the same time, it entered into an unsecured loan agreement with GCM Partners II, a fund controlled by its major shareholder Gatemore Capital Management, for a loan to the company of £2m.

As it previously announced, DX had been in discussions with Gatemore and its bankers HSBC over financing options for the company's standalone transformation strategy.

The proceeds of the property transaction and the Gatemore loan would be used primarily to repay the company's term loan with HSBC, which was the first step of an “essential comprehensive refinancing” of the company.

DX said it was currently in “close and constructive” discussions with certain key shareholders regarding the broader refinancing.

Its board said that was necessary because it identified a “near term material funding requirement”, over and above the company's existing resources, to address a working capital shortfall caused by DX’s recently-reduced levels of profitability, and to provide funds for the planned investment into improving the financial performance of the DX business.

“We welcome the support of our shareholder, Gatemore, alongside that of our bank, HSBC, as we proceed with our standalone transformation strategy, and will provide a further update on the Company's financing arrangements within coming weeks,” said DX chairman Bob Holt.

Liad Meidar, CIO and managing partner of Gatemore Capital Management, said the Gatemore loan enabled the company to pay down HSBC's term loan, while retaining the freight hub in Willenhall.

“This gives the company greater financial and operational flexibility, setting the stage for the refinancing.

“We expect to roll our loan shortly into the new financing, positioning DX with a healthy balance sheet and a new start under proven leadership.”

More news

13:05 Avanti Communications proposes debt-for-equity swap

Avanti Communications, the satellite services provider, has reached agreement with its major shareholder and most of its bondholders to restructure its $557m debts via a debt-for-equity swap.

12:29 Care facilities subject of TV investigation, Cambian confirms

Cambian Group issued an update to the market on Wednesday, reporting that on 10 November, it received a letter from an independent television production company informing it of its intention to broadcast a current affairs programme that will include undercover video footage at a number of care facilities managed by independent providers, three of which are operated by Cambian.

12:22 Idox warns on profits after revenue recognition hitch, CEO on sick leave

Idox warned that annual profits will be lower than it previously indicated due to trouble over revenue recognition, which has been complicated by the sudden absence of its chief executive due to illness.

12:05 London midday: Stocks steady after mixed jobs data, ahead of Fed announcement

London stocks were steady by midday on Wednesday as investors digested some mixed UK jobs data and looked ahead to the latest policy announcement from the Federal Reserve.

11:57 Hikma launches migraine injection treatment

Hikma Pharmaceuticals has launched its own version of an acute injected treatment for migraine headaches, dihydroergotamine mesylate. West-Ward's Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. According to IMS Health, US sales of Dihydroergotamine Mesylate Injection, USP were approximately $34.8 million in the 12 months ending October 2017. Riad Mechlaoui, Chief Executive Officer of Injectables said, "We are pleased to be adding Dihydroergotamine Mesylate Injection, USP to our Injectables portfolio in the US. We have a large portfolio of products and a pipeline of differentiated products to support future growth."

11:36 Brexit: Theresa May could be facing defeat over withdrawal bill

The British government is facing a rebellion in parliament after MPs requested an amendment calling for a “meaningful vote" on the Brexit deal before it is made final.

11:31 US pre-open: Stocks seen flat as investors eye Fed announcement

US futures pointed to a muted open on Wall Street on Wednesday as investors eyed the latest policy announcement and economic projections from the Federal Reserve.

11:23 Zotefoams to provide footwear foams exclusively to Nike

Zotefoams has entered into a strategic partnership with Nike, it announced on Wednesday, to develop footwear technology and supply materials for the global footwear, apparel and equipment company.

11:17 Dixons Carphone pledges to 'simplify' mobile business as profits plummet

Profits at Dixons Carphone crumpled in the first half as UK mobile phone customers continued to hold onto their handsets longer, leading the retailer to plan a restructuring of this business and pledge that the dividend will be kept steady.

11:05 Vela Technologies raises £0.75m in placing

Early-stage and pre-IPO technology investing company Vela Technologies has raised gross proceeds of £0.75m through a placing of 115,384,615 new ordinary shares at a price of 0.65p per share, it announced on Wednesday.